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Abstract 
Our recent studies revealed that focal alterations in breast myoepithelial cell layers sig-
nificantly impact the biological presentation of associated epithelial cells. As preg-
nancy-associated breast cancer (PABC) has a significantly more aggressive clinical course 
and mortality rate than other forms of breast malignancies, our current study compared 
tumor suppressor expression in myoepithelial cells of PABC and non-PABC, to deter-
mine whether myoepithelial cells of PABC may have aberrant expression of tumor 
suppressors. Tissue sections from 20 cases of PABC and 20 cases of stage, grade, and 
age matched non-PABC were subjected to immunohistochemistry, and the expression 
of tumor suppressor maspin, p63, and Wilms’ tumor 1 (WT-1) in calponin positive 
myoepithelial cells were statistically compared. The expression profiles of maspin, p63, 
and WT-1 in myoepithelial cells of all ducts encountered were similar between PABC 
and non-PABC. PABC, however, displayed several unique alterations in terminal duct 
and lobular units (TDLU), acini, and associated tumor tissues that were not seen in 
those of non-PABC, which included the absence of p63 and WT-1 expression in a vast 
majority of the myoepithelial cells, cytoplasmic localization of p63 in the entire epithelial 
cell population of some lobules, and substantially increasing WT-1 expression in vascular 
structures of the invasive cancer component. All or nearly all epithelial cells with aber-
rant p63 and WT-1 expression lacked the expression of estrogen receptor and pro-
gesterone receptor, whereas they had a substantially higher proliferation index than 
their counterparts with p63 and WT-1 expression. Hyperplastic cells with cytoplasmic 
p63 expression often adjacent to, and share a similar immunohistochemical and cyto-
logical profile with, invasive cancer cells. To our best knowledge, our main finings have 
not been previously reported. Our findings suggest that the functional status of 
myoepithelial cells may be significantly associated with tumor aggressiveness and inva-
siveness. 
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Introduction 
The normal and pre-invasive human breast epi-
thelium, which is the histological origin of over 80% of 
breast malignancies, is physically separated from the 
stroma by both the basement membrane and 
myoepithelial cells. The basement membrane is com-
posed of type IV collagen, laminins, and other mole-
cules, forming a continuous lining surrounding and 
attaching to myoepithelial cells [1-2]. Myoepithelial 
cells are joined by intercellular junctions and adhesion 
molecules, forming a continuous sheet that com-
pletely surrounds the normal duct system and a vast 
majority of the lobular units [3-4]. The predominant 
and phenotypic structural constituent of myoepithe-
lial cells is microfilament, which could be elucidated 
by immunohistochemistry with a number of com-
mercially available antibodies, including those to 
calponin, smooth muscle actin, smooth muscle my-
osin heavy chain, H-caldesmon, P-cadherin, and Cy-
tokeratins 5, 7, 14, and 17 [5]. In H&E stained sections, 
myoepithelial cells are in cuboid or spindle shape 
with pale cytoplasm and nucleus. Under an electronic 
microscope, normal myoepithelial cells have a sub-
stantially fewer or no distinct rough reticulum endo-
plasm, Golgi complex, secretory granules, and a very 
low level of proliferating activities, compared to the 
associated epithelial cells [3]. Thus, myoepithelial cells 
have been traditionally regarded as an idle and pas-
sive physical barrier with no significant active func-
tions [1-4].  
Recent studies, however, have suggested that 
myoepithelial cells may possess a number of active 
functions. One of the functions is the production of 
tumor suppressers, including maspin, Wilms’ tumor 1 
(WT-1), p63, and p73 [5-9]. In vitro and in vivo studies 
have shown that these tumor suppressors have sig-
nificant paracrine inhibitory functions against tumor 
growth and invasion [5-9]. Our recent studies re-
vealed that about 90% of morphologically distinct 
myoepithelial cells in normal and hyperplastic ducts 
had distinct expression of these tumor suppressors, 
whereas only about 70% of the myoepithelial cells in 
ducts with in situ breast cancer expressed these tumor 
suppressors [5,9]. Our studies also revealed that a 
subset of normal, hyperplastic, and pre-invasive ducts 
and acini harbored focal disruptions (the absence of 
myoepithelial cells resulting a gap larger than a com-
bined size of at least three myoepithelial cells) in their 
surrounding myoepithelial cell layers, and that a sub-
set of morphologically distinct myoepithelial cells 
completely lacked the expression of all myoepithelial 
cell phenotypic markers [10-19]. Ducts and acini with 
focally disrupted myoepithelial cell layers or 
myoepithelial cell layers lacked expression of tumor 
suppressors had a significantly higher rate of cell pro-
liferation, ER negativity, and expression of invasion 
related molecules than their morphologically similar 
counterparts with normal myoepithelial cell layers 
[10-19]. Together, these findings suggest that a reduc-
tion of tumor suppressor expression and focal dis-
ruption of the myoepithelial cell layers may signifi-
cantly contribute to tumor aggressiveness and inva-
siveness.  
Pregnancy-associated breast cancer (PABC) oc-
curs during pregnancy or within one year of delivery. 
Although the incidence of PABC is low, it is the sec-
ond most common cancer in pregnant women [20-23]. 
It has been well documented that a normal full-term 
of pregnancy is one of the most effective means of 
decreasing the lifetime-risk of breast cancer, whereas 
PABC is consistently associated with the most ag-
gressive clinical course and highest mortality rate 
among breast malignancies [20-23]. These seemingly 
conflicting impacts have been largely attributed to 
proliferation and differentiation of stem cells, and 
remodeling of the cellular microenvironment and 
extracellular matrix [22-23]. The specific molecular or 
cellular mechanism, or unique molecules that are di-
rectly linked to aggressiveness and invasiveness, 
however, have not been identified. As the myoepithe-
lial cell is the sole source of several tumor suppressors 
that have significant paracrine inhibitory function on 
tumor cell growth and invasion [5-9], our current 
study attempted to determine whether the myoepi-
thelial cell layer of PABC would have aberrant tumor 
suppressor expression.  
Materials and Methods   
Formalin-fixed, paraffin-embedded tissue blocks 
from 20 patients with PABC, 20 cases of stage, grade, 
and age matched non-PABC, and 20 reduction 
mammoplasties of individuals with no family history 
of breast cancer, and no mammographic or histologi-
cal breast abnormalities were selected from the cases 
sent to our institute for consultation with patients’ 
consent. All selected PABC and non-PABC cases con-
tained normal, hyperplastic, in situ, or invasive com-
ponents. Consecutive sections at 4-5 μm thickness 
were prepared and placed on positively charged 
slides. The first and last sections from each case were 
stained with hematoxylin and eosin (H&E) for mor-
phological classification, based on our published cri-
teria [24], which confirmed all the initial diagnosis.   
Mouse monoclonal antibodies against human 
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myoepithelial cell phenotypic marker, and maspin 
(clone: EAW24) were purchased from Novocastra 
Laboratories Ltd (Newcastle, UK). Mouse monoclonal 
antibodies against human WT-1 protein (clone: 
6F-H2) and p63 protein (clone: 4A4) were purchased 
from Cell Marque (Hot Springs, AR). A mouse mono-
clonal antibody for proliferation marker Ki-67 (Clone: 
MM1) was purchased from DAKO (Capterria, CA). 
Mouse monoclonal antibodies against human estro-
gen receptor (ER; clone: ER-6F11) and progesterone 
receptor (PR; clone: PGR-312) were purchased from 
Novocastra Laboratories Ltd (Newcastle, UK). The 
secondary antibody, the ABC detection kit, and the 
DAB chromogen kit were purchased from Vector 
Laboratories (Burlingame, CA). A red chromogen, AP 
red, was purchased from Zymed Laboratories (South 
San Francico, CA). Sets of four adjacent sections were 
subjected to immunohistochemical staining using the 
protocol provided by the manufacturers.  
To assess the specificity of the immunostaining, 
three technical approaches were used. First, different 
negative controls were used, which included (1) the 
substitution of the primary antibody with normal 
serum, (2) the omission of the secondary antibody 
from the immunostaining sequence, (3) serial dilu-
tions of the primary antibody. Second, the same im-
munostaining protocol was used on the same cases, 
but substituting with different detection system and 
substrates. Third, the immunostaining procedure was 
repeated at least twice using the same protocol and 
under the same condition and immunostained sec-
tions were independently evaluated by at least two 
investigators. A given cell was considered immuno-
reactive to a given antibody when distinct immuno-
reactivities were consistently seen in either its cyto-
plasm nucleus, whereas all negative controls were 
devoid of distinct immunostaining.  
To further confirm the specificity of calponin and 
WT-1 immunostaining, which occasionally cross-react 
with fiberoblasts and endothelial cells, a set of three 
adjacent sections from each case were subjected to 
immunohistochemical staining with molecular anti-
bodies to cytokeratin (CK) 5 (clone: XM26), 14 (clone: 
LL002), and 17 (clone: E3; Novocastra Laboratories 
Ltd, Newcastle, UK), which are exclusively expressed 
in myoepithelial cells and cells with the epithelial 
origin.  
From each case, 4-5 randomly selected duct and 
acinar clusters of each tissue component were photo-
graphed, and enlarged printers were made. As cal-
ponin is uniformly expressed in all or nearly all 
morphologically identifiable myoepithelial cells in 
H&E stained sections, the number of myoepithelial 
cells in a given duct or acinus was first determined in 
calponin stained sections. Using the obtained number 
as references, the number of positive and negative 
myoepithelial cells for each tumor suppressor in each 
duct or acinus was counted, and the numbers in dif-
ferent ducts and acini were added and averaged. The 
averaged percentages of tumor suppressor expressing 
cells in morphologically similar tissue components of 
PABC and non-PABC were statistically compared 
with the Pearson’s Chi-squared test. The proliferation 
indexes in morphologically similar ducts or acini with 
and without aberrant p63 and WT-1 expression were 
similarly compared. Statistical significance was de-
fined as the p-value < 0.05.  
Results  
Distinct immunoreactivities to calponin, p63, 
maspin, and WT-1 were elusively or preferentially 
seen in myoepithelial cells. WT-1, however, was also 
seen in endothelial cells and duct and acinar lumen. 
The negative controls were d e v o i d  o f  i m m u n o r e a c -
tivities to any of these molecules. Immunoreactivities 
to calponin, maspin, and WT-1 were predominantly 
seen in the cytoplasm. Immunoreactivities to Ki-67, 
ER, and PR were seen exclusively in the nuclei. Im-
munoreactivities to p63 were predominantly seen in 
the nuclei, but also seen in the epithelial cells of some 
cases (see below). Immunoreactivities to cytokeratin 5, 
14, and 17 were exclusively present in the cytoplasm 
of myoepithelial cells.  
In reduction mammoplasties and the morpho-
logically clear-cut normal tissue component of both 
PABC and non-PABC, epithelial and myoepithelial 
cells were roughly equal in number, and all or nearly 
all the myoepithelial cells were similar in shape and 
size. Over 90% of morphologically distinct myoepi-
thelial cells were uniformly immunoreactive to the 
myoepithelial cell phenotypic marker calponin, and 
about 90% of calponin positive myoepithelial cells 
co-expressed maspin, WT-1, and p63 (Fig. 1).   
In hyperplastic and in situ malignant tissue 
components of non-PABC, the relative number of 
myoepithelial cells was significantly fewer than that 
of epithelial cells, and the shape and size of myoepi-
thelial cells varied substantially. Over 90% of mor-
phologically distinct myoepithelial cells, however, 
were uniformly and strongly immunoreactive to cal-
ponin immunostaining. Some ducts with malignant or 
hyperplastic lesions, however, harbored morpho-
logically distinct myoepithelial cells that were 
strongly immunoreactive to calponin, whereas lacked 
the expression of p63 and WT-1 (Fig. 2).  
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Figure 1. Calponin and tumor suppressor expression in reduction mammoplasties. A set of four adjacent sections were 
immunostained for calponin and mapin, p63, and WT-1. Arrows identify myoepithelial cell layers. Note that about 90% of 
the myoepithelial cells in a small lobule are positive for calponin, and also co-express maspin, p63, and WT-1. a, c, e, and g: 
100X; b, d, f, and h: a higher (300X) magnification of a, c, e, and g, respectively.  Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
86
 
Figure 2. Lack of p63 and WT-1 in calponin positive myoepithelial cells A set of four adjacent sections were immunostained 
for calponin and mapin, p63, and WT-1. Arrows identify myoepithelial cell layers. Note that in a hyperplastic duct, a number 
of myoepithelial cells lack p63 and WT-1 expression, whereas they are positive for calponin and maspin. a, c, e, and g: 100X; 
b, d, f, and h: a higher (400X) magnification of a, c, e, and g, respectively.  
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In hyperplastic and in situ malignant compo-
nents of PABC, the overall pattern of myoepithelial 
cell alterations and tumor suppressor expression was 
similar to that of non-PABC in all ducts encountered. 
PABC, however, displayed several unique properties 
that were not seen in their non-PABC counterparts:  
1. Significantly fewer dusts encountered.  
In all 20 cases, normal or pathologically altered 
ducts accounted for only about 10% of the total 
epithelial cell population. Most ducts were distributed 
in the inter-lobular space.  
2. Significantly decreased p63 and 
WT-1 expression in acini and ter-
minal duct and lobular units 
(TDLU).  
I n  s e t s  o f  f o u r  i m m e d i a t e  
consecutive sections, calponin 
and maspin were uniformly ex-
pressed in all or nearly all mor-
phologically distinct myoepithe-
lial cells (Fig. 3a-3b). In sharp 
contrast, in about 80% of the 
acini and TDLU, only about 10% 
and 30% of calponin positive 
myoepithelial cells showed 
WT-1 and p63 expression, re-
spectively (Figs. 3-4; Table 1). 
Under high magnification, all or 
nearly all acini and TDLU with 
reduced p63 and WT-1 expression showed fragmen-
tations or small focal disruptions in the surrounding 
myoepithelial cell layers. In about 20% of the acini and 
TDLU, however, all or nearly all morphologically 
distinct myoepithelial cells uniformly expressed all 
four markers. These acini and TDLU were arranged as 
morphologically distinct lobules with variable sizes. 
These lobules were generally separated by stromal 
tissues from adjacent lobules that showed signifi-
cantly reduced p63 and WT-1 expression (data not 
shown).  
 
 
Figure 3. Reduced p63 and WT-1 
expression in calponin and maspin 
positive myoepithelial cells of PABC. 
Two sets of four adjacent sections 
were immunostained for calponin 
and mapin, p63, and WT-1. Aster-
isks identify normal ducts in the 
inter-lobular space. Arrows identify 
myoepithelial cell layers. Note that a 
vast majority of the myoepithelial 
cells in normal ducts are positive for 
all four markers, whereas a vast 
majority of the myoepithelial cells in 
the acini lack p63 and WT-1 ex-
pression. 200X.  Int. J. Biol. Sci. 2009, 5 
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Figure 4. Reduced p63 and WT-1 expression in calponin and maspin positive myoepithelial cells of PABC. Two sets of four 
adjacent sections were immunostained for calponin and mapin, p63, and WT-1. Asterisks identify normal ducts in the 
inttra-lobular space. Arrows identify myoepithelial cell layers. Note that a vast majority of the myoepithelial cells in normal 
ducts are positive for all four markers, whereas a vast majority of the myoepithelial cells in the acini lack p63 and WT-1 
expression. 200X.  
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Table 1. Comparison of tumor suppressor expression in myoepithelial cells of PABC and non-PABC  
Tissue Type   Calponin (+) ME cells   With Maspin (%)   With p63 ((%)   With WT-1 (%)    p  
Non-PABC ducts   5,000    4,637 (92.7%)    4,582 (91.6%)   4,512 (90.2%)    
Acini or TDLU   5,000    4,201 (84.0%)    4,120 (82.4%)   4,034 (80.1%)   >0.05  
PABC ducts   2,000    1,806 (90.3%)    1,796 (89.8%)   1,724 (86.2%)    
Acini or TDLU   5,000    4,015 (80.3%)    1,560 (31.2%)   541 (10.8%)   <0.01  
 
 
3. Cytoplasmic p63 expression in the entire epithelial cell 
population of some lobules.  
In 8 (40%) cases, distinct 
cytoplasmic p63 expression 
was seen in a subset of epithe-
lial cells. The number of cells 
with cytoplasmic p63 expres-
sion among cases varied sig-
nificantly, from a few acinar 
clusters to over 30% of the en-
tire epithelial cell population. 
These normal or hyperplastic 
p63 expressing cells were ar-
ranged as lobules, in which all 
or nearly all the epithelial cells 
uniformly expressed high lev-
els of p63, in sharp contrast to 
adjacent normal ducts, which 
showed distinct nuclear p63 
expression (Fig. 5). These cyto-
plasmic p63 expressing cells 
were often adjacent and cy-
tologically similar to invasive 
cancer cells, which also showed distinct cytoplasmic 
p63 expression (Figs. 5g-5h).   
 
 
Figure 5. Cytoplasmic p63 ex-
pression in epithelial cells of 
PABC. Four sections from four 
different cases were immu-
nostained for p63. Arrows identify 
myoepithelial cells with nuclear 
p63 localization in normal ducts. 
Note that the epithelial cells in 
some acinar clusters or the entire 
lobule show cytoplasmic p63 ex-
pression. In addition, some lobules 
with hyperplastic cells that show 
cytoplasmic p63 expression are 
immediately adjacent to, and share 
a similar morphological and im-
munohistochemical profile with, 
invasive cancer cells (g-h) a, c, e, 
and g: 100X; b, d, f, and h: a higher 
(400X) magnification of a, c, e, and 
g, respectively.  Int. J. Biol. Sci. 2009, 5 
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4. Increasing WT-1 expression 
in micro-vessels of the malig-
nant tissue component.  
In normal and hyper-
plastic tissue components, 
most micro-vessels showed 
n o  d i s t i n c t  o r  v e r y  w e a k .  
WT-1 expression. In the ma-
lignant tissue component, 
however, all or nearly all 
morphologically identifiable 
micro-vessels were strongly 
immunoreactive to WT-1 
(Fig. 6). The expression of 
WT-1 in vascular structures 
was confirmed by different 
immuno-detection systems 
with different chromogens 
(Fig. 6), and also by immu-
nohistochemistry with en-
dothelial cell specific mark-
ers CD31 (data not shown).  
 
Figure 6. Increased cell 
proliferation in normal ap-
pearing epithelial cells near 
invasive lesions of PABC. 
Four sections from four dif-
ferent cases were double 
immunostained for calponin 
and Ki-67. N: normal; C: 
invasive cancer. Note that 
some morphologically nor-
mal appearing acinar clusters 
in the inter-lobular space or 
near the invasive cancer 
show substantially higher cell 
proliferation than their 
counterparts distant from 
the invasive lesion. a, c, e, and 
g: 80X; b, d, f, and h: a higher 
(200) magnification of a, c, e, 
and g, respectively.  
 
5. Significantly elevated epithelial cell proliferation.  
In sections double immunostained with myoepi-
thelial cell and proliferation markers, a vast majority 
of the proliferating cells were seen in acinar clusters 
with focally disrupted myoepithelial cell layers, 
which consistently showed aberrant p63 or WT-1 ex-
pression. The size of these acinar clusters varied sub-
stantially and all these clusters showed a distinct 
boundary with their adjacent counterparts (Fig 7a-7b). 
A vast majority of these acinar clusters were immedi-
ately adjacent to invasive cancers (Fig.7c-7h).  Int. J. Biol. Sci. 2009, 5 
 
 
http://www.biolsci.org 
91
 
 
Figure 7. Increased WT-1 expression in invasive lesions of PABC. Four sections from four different cases were double 
immunostained for WT-1. N: normal; C: invasive cancer. Note that the invasive tissue component has substantially more 
small vessels with WT-1 expression. a, c, e, and g: 80X; b, d, f, and h: a higher (200) magnification of a, c, e, and g, respectively.  
 Int. J. Biol. Sci. 2009, 5 
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6. Significantly reduced ER and 
PR expression.  
In non-PABC, about 
50% of the acinar and duct 
cells in over 80% of the cases 
showed distinct ER or PR 
expression (data not shown). 
In sharp contrast, all cells in 
TDLU and acini with aber-
rant p63 and WT-1 expres-
sion lacked distinct ER or PR 
expression in all cases (data 
not shown).  
The significant reduc-
tion of p63 and WT-1 ex-
pression in calponin positive 
myoepithelial cells of PABC 
was confirmed by immuno-
histochemistry for CK 5, 14, 
a n d  1 7 .  I n  s e t s  o f  f o u r  i m -
mediate adjacent sections, all 
or nearly all morphologically 
distinct myoepithelial cells 
were uniformly immunore-
active to CK 5, 14, and 17, 
but only about 10% and 30% 
of CK positive cells showed 
WT-1 and p63 expression, 
respectively (Fig 8).   
 
 
Figure 8. Reduced p63 and 
WT-1 expression in cytokeratin 
positive myoepithelial cells of 
PABC. Two sets of four adja-
cent sections from two different 
cases were immunostained for 
CK 5, CK 14, p63, and WT-1, 
respectively. Arrows identify 
myoepithelial cells in normal 
ducts with expression of dif-
ferent markers. Note that all or 
nearly all morphologically dis-
tinct myoepithelial cells express 
CK 5 and CK 14, while a vast majority of the CK-positive cells lack p63 and WT-1 expression. 200X.  
 
Discussion and Conclusions   
The overall expression pattern of tumor sup-
pressors in myoepithelial cells and biological presen-
tations in epithelial cells seen in our current study are 
in total agreement with previous reports that the ex-
pression of p63 and WT-1 is inversely correlated with 
breast tumor progression and invasion [5-9]. Our 
findings of WT-1 expression in the vascular structure 
are in agreement with a recent study, which reported 
that “Endothelial WT1 expression was detected 95% 
of 113 tumors of different origin” [25]. To our best 
knowledge, our findings of the absence of p63 and 
WT-1 expression in a vast majority of the myoepithe-Int. J. Biol. Sci. 2009, 5 
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lial cells of acini and TDLU, cytoplasmic localization 
of p63 in the entire epithelial cell population of some 
lobules, increasing WT-1 expression in vascular 
structures of the invasive tissue component, and sub-
stantially different p63 and WT-1 expression between 
ducts and acini or TDLU, in PABC, however, have not 
been previously reported.  
The absence of p63 and WT-1 expression in most 
myoepithelial cells in acini and TDLU of PABC is 
likely to result from two correlated mechanisms: (A) 
Genetic defects in myoepithelial cell self-renewal-related 
genes. As both p63 and WT-1 play significant roles in 
the early developmental of several organs and sys-
tems [27-29], it is possible that at the early stage of 
breast morphogenesis, the breasts of these patients 
may have exposed to certain external or internal in-
sults that may have caused permanent damages in 
DNA structures of some primitive stem cells. These 
DNA structural damages resulted in the inactivation 
of, or defects in, myoepithelial cell renewal-related 
genes, which impaired the myoepithelial cell replen-
ishment process to replace the aged or injured 
myoepithelial cells, resulting in a “senesced” 
myoepithelial cell population with significantly re-
duced p63 and WT-1 expression. Consistent with this 
possibility is the fact that the expression of maspin, a 
tumor suppressor that is not involved in early devel-
opment [6], is not affected in all PABC cases in this 
study. (B) Simultaneous activation and proliferation of 
multiple tumor stem cells. The DNA structural damages 
may have also caused the inactivation of, or defects in, 
cell cycle control-and apoptosis-related genes in the 
epithelial cell population, which allow these cells to 
proliferate to form different acinar clusters or TDLU 
with the same genetic defects. These acinar clusters or 
TDLU may progress rapidly after external or internal 
insults, leading to the early occurrence of breast can-
cer at young ages. On the other hand, these clusters 
may become maturation-arrested after a few cycles of 
cells divisions, but remain the potential for unlimited 
proliferation and multi-lineage differentiation. During 
the last few weeks of pregnancy, these clusters are 
activated and simultaneously proliferating in re-
sponding to a sharp increase of estrogen, progester-
one, and other hormones [21-23]. As the myoepithelial 
cell population lacks the receptors for these hor-
mones, it may not be able to undergo vigorous pro-
liferations to match the dramatic increase of epithelial 
cells, which could result in the over-stretch or even 
focal disruptions of the myoepithelial cell layers. 
Consistent with this possibility is the following facts: 
(1) the proliferation index is significantly higher in 
acini and TDLU with aberrant p63 and WT-1 expres-
sion, (2) the morphological and immunohistochemical 
profiles differ substantially among lobules, and (3) the 
entire cell population of some morphologically nor-
mal appearing lobules shared the same malignant 
cytological features and proliferation index with their 
adjacent invasive counterparts (as shown in Fig 7). 
This possibility is also supported by recent studies in 
human prostate tumors, which detected a DNA phe-
notype that is identical to that of invasive cancer in 
some “healthy” men, and in morphologically normal 
prostate tissues adjacent to prostate cancer [30-33].  
Cytoplasmic p63 expression in the entire epithe-
lial cell population of some lobules is likely to results 
from aberrant transportation of the p63 protein. Simi-
lar to the p53 protein, p63 is synthesized in the cyto-
plasm and constantly transported through the nuclear 
pore complex into the nuclei [34-35]. A number of 
factors, including alterations of the elements and 
molecules involved in p63 nucleo-cytoplasmic trans-
portation could significantly impact the p63 cellular 
trafficking, and consequently alter its sub-cellular 
localization [34-35]. A previous study from our lab 
showed that only cells exhibiting secretory changes or 
secretory carcinomas had cytoplasmic p63 expression 
[36]. It is possible that the secretory products in PABC 
may form protein-protein complexes with p63, which 
prevent the import of p63 protein into the nuclei. 
Consistent with this possibility is the fact that some 
proteins could form protein-protein complexes with 
p53, which results in accumulation of p53 in the cyto-
plasm [37-38]. Although the clinical significance of 
cytoplasmic p63 expression in human breast is un-
known, a similar morphological and immunohisto-
chemical profile between cytoplasmic p63 expressing 
hyperplastic and adjacent invasive cancer cells (as 
shown in Figs. 5g-5h) suggests the possibility of direct 
transformation of hyperplastic cells to invasive le-
sions. Consistent with this possibility are the facts that 
cutoplasmic localization of p63 is associated with poor 
patient survival in lung cancer and is also associated 
with tumor grade in meningiomas [39-40].  
The differential WT-1 expression in myoepithe-
lial and endothelial cells of the same case could po-
tentially result from focal degeneration of aged or 
injured myoepithelial cells and the resultant 
auto-immunoreactions for the following reasons. 
First,  myoepithelial cells belong to a self-renewal 
population that has to consistently proliferate and 
differentiate to replace the aged and injured myoepi-
thelial cells. Any internal and external insults that 
impair the replenishment process could result in a 
“senesced” myoepithelial cell population that is mor-
phologically distinct, whereas may loss the expression 
of tumor suppressors and other markers. Second, the 
degradation products of degenerated myoepithelial Int. J. Biol. Sci. 2009, 5 
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cells and the diffusible molecules secreted by the 
overlying tumor cells could function as self-epitopes 
to attract the infiltration of immunoreactive cells, re-
sulting in localized chronic inflammation, which 
could directly incite angiogenesis or cause cellular 
and genomic damages [41-42].  WT-1 expression in 
endothelial cells could potentially result from or re-
flect the recapitulation of the early events of 
morphogenesis, which undergo extensive cell prolif-
eration and vascularization. As the WT-1 encodes a 
transcription factor that binds to GC-rich sequences 
and regulates the expression of several genes of the 
growth factor family [43-47], it is likely that WT-1 
might also regulate the expression of the vascular 
growth factor. Consistent with our speculation is the 
fact that the normal development and tumor invasion 
share the same mechanism for epithelial-branching 
and migration. It is also possible that, elevated WT-1 
expression in endothelial cells may result from alter-
native splicing that results in an isoform of WT-1 
mRNA, which has high affinity to bind to the vascular 
growth factor receptor. Consistent with our specula-
tion is the fact that a recent study has shown that 
WT-1 17AA(-)/KTS isoform could induce morpho-
logical changes, and promotes cell migration and in-
vasion in vitro, whereas other isoforms failed to in-
duce similar changes under the same condition [48].  
The specific cellular or molecular mechanism 
accounting for a potential correlation between tumor 
suppressor expression in myoepithelial cells and bio-
logical behavior in tumor cells is unknown, but is 
likely to result from the resultant consequences of 
aberrant tumor suppressor expression and focal dis-
ruptions in the myoepithelial cell layers. As the epi-
thelium is normally devoid of both blood vessels and 
lymphatic ducts, and thus, totally relies on the stroma 
for its needed materials for normal functions and even 
survival, a focal myoepithelial cell layer disruption 
(FMCLD) could have several consequences, including 
(1) an increase of permeability for oxygen, nutrients, 
and growth factors, which selectively triggers the exit 
of stem or progenitor cells from quiescence [49-50], (2) 
the exposure of luminal cells to different cytokines, 
which facilitates vasculogenic mimicry and tumor 
angiogenesis [51-52], (3) The physical contact between 
luminal and stromal cells, which augments the ex-
pression of stromal MMP and facilitates epithe-
lial-mesenchymal transition (EMT) and cell motility 
[53-54], and (4) The physical contact between luminal 
and immunoreactive cells, which directly cause ge-
nomic or cellular damages that trigger a cascade reac-
tion of malignant transformation [41-42]. These al-
terations could individually or collectively trigger 
elevated proliferation in acinar clusters with aberrant 
tumor suppressor expression or with focally dis-
rupted myoepithelial cell layers, which leads to the 
enlargement of FMCLD and stretched-out of the re-
sidual myoepithelial cells. Eventually, the entire 
epithelial cell population in these clusters completely 
loses their surrounding structures and transform di-
rectly to a new microenvironment that favors epithe-
lial- mesenchymal transition and cell motility. Al-
though these cells might not possess all the properties 
of invasive cancer cells, the changed microenviron-
ment may act as the second “hit” to trigger a cascade 
reaction of malignant transformation [22-23]. As some 
of those acinar clusters with focally disrupted 
myoepithelial cell layers may represent a population 
of mutation-arrested stem cells and retain the poten-
tial for unlimited proliferation and multi-lineage dif-
ferentiation, they may rapidly progress to invasive or 
metastatic breast lesions. In addition, hyperplastic 
acinar cells with cytoplasmic p63 expression may di-
rectly transform into invasive lesions.  
No definite conclusions, however, could be 
drawn at present, since our sample size is small, and 
the clinical follow-up data are not available. On the 
other hand, if confirmed by further studies, our find-
ings are likely to have several significant scientific and 
clinical implications. First, as a vast majority of the 
breast malignancies are originated from TDLU, the 
development of more applicable methods to quanti-
tatively assess the expression of p63 and WT-1 ex-
pression in this site may be more effective than cal-
ponin immunostaining for early detection of breast 
cancer. Second, the elucidation of the mechanism of 
cytoplasmic p63 expression may lead to the devel-
opment of new therapeutic agents to target can-
cer-related molecules in the cytoplasm or nuclei. 
Third, the development of different agents to target 
WT-1 in endothelial cells may have significant thera-
peutic value. Fourth, the development therapeutic 
agent to stimulate myoepithelial cell self-renewal or to 
prevent myoepithelial cell degradation may be more 
effective than the traditional approaches for breast 
cancer intervention and prevention.  
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